Exploratory research to analyze the effects of disease susceptibility genes on therapeutic response and autoantibodies in rheumatoid arthritis

Exploratory research to analyze the effects of disease susceptibility genes on therapeutic response and autoantibodies in rheumatoid arthritis - Research to analyze the effects of disease susceptibility genes on therapeutic response and autoantibodies in rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040279

Enrollment

250

Registered

2020-05-01

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have already participated in previous studies associated with rheumatoid arthritis at our institution and who have obtained consent for this study.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Comparison of clinical disease activity at 3, 6, and 12 months after the treatment between treatments with targeted synthetic/biological DMARDs and conventional synthetic DMARDs according to the presence or absence of human leukocyte antigen(HLA) and shared epitope (SE).	—

Secondary

Measure	Time frame
Comparison of ultrasound activity at 6 and 12 months after the treatment between treatments with targeted synthetic/biological DMARDs and conventional synthetic DMARDs according to the presence or absence of human leukocyte antigen(HLA) and shared epitope (SE). Comparison of autoantibody titers at 3 and 12 months after the treatment between treatments with targeted synthetic/biological DMARDs and conventional synthetic DMARDs according to the presence or absence of HLA and SE.	—

Measure

Time frame

Comparison of ultrasound activity at 6 and 12 months after the treatment between treatments with targeted synthetic/biological DMARDs and conventional synthetic DMARDs according to the presence or absence of human leukocyte antigen(HLA) and shared epitope (SE). Comparison of autoantibody titers at 3 and 12 months after the treatment between treatments with targeted synthetic/biological DMARDs and conventional synthetic DMARDs according to the presence or absence of HLA and SE.

—

Countries

Japan

Contacts

Public ContactYushiro Endo

Nagasaki University Hospital Department of Immunology and Rheumatology

yushiro19861105@hotmail.co.jp095-819-7260

Outcome results